Quick Answer
Phathom Pharmaceuticals, Inc. reported Total Revenue of $175.11 million for fiscal year 2025.
Phathom Pharmaceuticals, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $175.11M +216.9% |
$55.25M +8001.5% |
$682.0K | $0.00 | — | — |
| Net Income | -$221.25M +33.8% |
-$334.33M -65.8% |
-$201.59M -2.0% |
-$197.72M -37.4% |
-$143.88M -11.5% |
-$129.07M +49.4% |
| Diluted EPS | -$3.03 +42.7% |
-$5.29 -34.6% |
-$3.93 +22.2% |
-$5.05 -29.8% |
-$3.89 | — |
| Total Assets | $259.15M -31.5% |
$378.32M -8.6% |
$413.84M +151.1% |
$164.81M -13.0% |
$189.43M -35.8% |
$295.11M +14.7% |
| Cash and Equivalents | $129.97M -56.3% |
$297.26M -22.1% |
$381.39M +145.5% |
$155.38M -15.2% |
$183.26M -36.3% |
$287.50M +17.9% |
| Long-Term Debt | $209.09M +3.8% |
$201.41M +46.1% |
$137.84M +44.7% |
$95.26M +6.2% |
$89.67M +126.2% |
$39.63M +74.0% |
| Stockholders Equity | -$438.17M -72.8% |
-$253.58M -248.5% |
-$72.76M +2.7% |
-$74.81M -203.7% |
$72.16M -62.9% |
$194.27M -14.8% |
| R&D Expense | $32.78M -3.8% |
$34.08M -31.7% |
$49.90M -30.2% |
$71.44M -1.2% |
$72.34M -26.3% |
$98.15M +381.7% |
| Operating Income | -$159.99M +42.3% |
-$277.47M -65.8% |
-$167.31M +3.0% |
-$172.44M -27.7% |
-$135.08M -7.5% |
-$125.67M -18.3% |
| Gross Profit | $152.51M +222.6% |
$47.28M +9080.4% |
$515.0K | $0.00 | — | — |
| Shares Outstanding | 71.42M +4.2% |
68.52M +18.2% |
57.97M +39.8% |
41.47M +35.9% |
30.51M +7.0% |
28.52M +15.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $49.50M | +202.7% | +25.3% |
| Net Income | September 30, 2025 | -$29.97M | +65.0% | +60.5% |
| Diluted EPS | September 30, 2025 | -$0.41 | +68.9% | +61.0% |
| Total Assets | September 30, 2025 | $240.29M | -37.9% | -4.0% |
| Cash and Equivalents | September 30, 2025 | $135.16M | -59.6% | -9.6% |
| Long-Term Debt | September 30, 2025 | $207.09M | +17.8% | +1.0% |
| Stockholders Equity | September 30, 2025 | -$422.53M | -125.8% | -4.1% |
| R&D Expense | September 30, 2025 | $7.03M | -19.2% | -22.6% |
| Operating Income | September 30, 2025 | -$15.27M | +78.4% | +74.5% |
| Gross Profit | September 30, 2025 | $43.31M | +209.5% | +25.7% |
| Shares Outstanding | September 30, 2025 | 71.04M | +4.0% | +1.3% |
- Phathom Pharmaceuticals, Inc. reported Total Revenue of $175.11 million for fiscal year 2025.
- Phathom Pharmaceuticals, Inc. showed an increase of +216.9% in Total Revenue compared to the prior fiscal year.
- Phathom Pharmaceuticals, Inc. reported Net Income of -$221.25 million for fiscal year 2025.
- Phathom Pharmaceuticals, Inc. showed an increase of +33.8% in Net Income compared to the prior fiscal year.
- Phathom Pharmaceuticals, Inc. reported Diluted EPS of $3.03 per share (loss) for fiscal year 2025.
- Phathom Pharmaceuticals, Inc. showed an increase of +42.7% in Diluted EPS compared to the prior fiscal year.
- Phathom Pharmaceuticals, Inc. reported Total Assets of $259.15 million for fiscal year 2025.
- Phathom Pharmaceuticals, Inc. showed a decrease of -31.5% in Total Assets compared to the prior fiscal year.
- Phathom Pharmaceuticals, Inc. reported Cash and Equivalents of $129.97 million for fiscal year 2025.
- Phathom Pharmaceuticals, Inc. showed a decrease of -56.3% in Cash and Equivalents compared to the prior fiscal year.
- Phathom Pharmaceuticals, Inc. reported Long-Term Debt of $209.09 million for fiscal year 2025.
- Phathom Pharmaceuticals, Inc. showed an increase of +3.8% in Long-Term Debt compared to the prior fiscal year.
- Phathom Pharmaceuticals, Inc. reported Stockholders Equity of -$438.17 million for fiscal year 2025.
- Phathom Pharmaceuticals, Inc. showed a decrease of -72.8% in Stockholders Equity compared to the prior fiscal year.
- Phathom Pharmaceuticals, Inc. reported R&D Expense of $32.78 million for fiscal year 2025.
- Phathom Pharmaceuticals, Inc. showed a decrease of -3.8% in R&D Expense compared to the prior fiscal year.
- Phathom Pharmaceuticals, Inc. reported Operating Income of -$159.99 million for fiscal year 2025.
- Phathom Pharmaceuticals, Inc. showed an increase of +42.3% in Operating Income compared to the prior fiscal year.
- Phathom Pharmaceuticals, Inc. reported Gross Profit of $152.51 million for fiscal year 2025.
- Phathom Pharmaceuticals, Inc. showed an increase of +222.6% in Gross Profit compared to the prior fiscal year.
- Phathom Pharmaceuticals, Inc. reported Shares Outstanding of 71.42 million shares for fiscal year 2025.
- Phathom Pharmaceuticals, Inc. showed an increase of +4.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: